mergers

View All

Cancer, diabetes and eczema on list; AbbVie’s Humira; Teva weighs $2B; Fresenius in buyout talks

Cancer, diabetes and eczema star in 2017 top-launch list Launch prognostications are getting more attention than ever as they come out with “Drugs to Watch” list, and the highlights of different drugs shows what might work this year. By 2021, some of the drugs in the list are expected to bring in $16 billion, shared...

Find More

Therapeutics
Valeant’s asset-sale; Sanofi coughs up $19.8M; Sanofi’s Genzyme; India’s Alkem; GSK’s inhalers

Valeant's asset-sale woes continue as Stada, Mundipharma lowball iNova bids Embattled Valeant has promised its investors $8 billion in asset sales—but as the company’s latest deal struggles continue to demonstrate, getting there may not be so easy. The bids rolling in for Valeant’s Australian iNova subsidiary aren’t...

Find More

GSK consolidates DT and TT vaccine, AZ gears up for FDA filing, Novartis comes up with flex pricing, Concordia reports loss

GSK consolidates DT and TT vaccine production in Hungary plant, adding 100 jobs With GlaxoSmithKline’s vaccines sales expanding, it figures it needs expanded production as well and some of that will happen at a 10-year-old plant in Hungary as well as Germany. GlaxoSmithKline said on Monday that it would invest £40 m...

Find More

Clinigen and Eisai team up; Sanofi, Lonza enter; Fidia to acquire; J&J completes acquisition

Clinigen and Eisai partner to offer Halaven for metastatic breast cancer in South Africa Eisai has partnered with Clinigen Group to distribute Halaven (eribulin) in South Africa for the treatment of women with metastatic breast cancer. Discovered and developed by Eisai, Eribulin is a synthetic variant of microtubule...

Find More

Therapeutics
PMV Raises; Argos Shares Plummet; Cidara Flunks in; Sarepta Sells to Gilead; Novartis and NHS Ayrshire & Arran launch

PMV Pharma Raises $74M, Aiming to Hit Cancer’s Hard Target- P53 PMV Pharmaceuticals is the latest startup to load up with cash in an attempt to home in on one of the toughest targets in cancer biology: the tumor suppressor protein known as p53. The company raised a $74 million Series B round from Topspin Biotech Fun...

Find More

ALCMI, ALCF and Scancell partner; Sun unloads Ohm Labs plants; Takeda and Ovid join; Guardant and MD Anderson collaborate; Glooko and Ascensia integrate

ALCMI, ALCF and Scancell partner to evaluate SCIB2 cancer vaccine for NSCLC The Addario Lung Cancer Medical Institute (ALCMI) and the Bonnie J. Addario Lung Cancer Foundation (ALCF) have collaborated with UK-based Scancell to assess SCIB2 cancer vaccine to treat patients with non-small-cell lung cancer (NSCLC). SCIB...

Find More

Payers block EpiPen; Allergan charged; AbbVie’s Humira; Baxter paying $18M

Payers block Kaléo's expensive EpiPen challenger Kaléo reintroduced its Auvi-Q last week at a list price of $4,500 for a two-pack in an effort to capture some market share from Mylan’s EpiPen, which is listed at about $600 for a two-pack. Auvi-Q is set to launch next month. Under Kaléo’s pricing strategy, Auvi-Q wil...

Find More

The Global M&A Frenzy Drops in the 3rd Quarter

The value of announced mergers and acquisitions (M&A) worldwide fell 27% to $753 billion in the third quarter of 2016, as the companies have become apprehensive in terms of overpaying, which totally prevented the repeat of last year's deal-making frenzy. The Thomson Reuters M&A data is of the view that the f...

Find More